SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

002603

CNE1000015S0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 16/07/2024 BST			5-day change	1st Jan Change
15.9 ^CNY	+1.66%		+7.43%	-31.08%

04-26	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-26	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 13, 2018.

January 02, 2019

From December 12, 2018 to December 31, 2018, the company has repurchased 4,330,100 shares, representing 0.36% for CNY 45.92 million. With this, the company has completed the repurchase of 4,330,100 shares, representing 0.36% for CNY 45.92 million under the buyback announced on December 13, 2018.

Latest news about Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug	12-06	MT
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4%	11-23	MT
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules	11-17	MT
Yiling Pharmaceutical Presents Clinical Data on Cardiovascular Drug at Beijing Conference	11-17	MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Yiling Pharmaceutical Gets Green Light to Trial Acute Myeloid Leukemia Drug	24/10/23	MT
Yiling Pharmaceutical Gets Greenlight to Trial G201-Na Capsules	12/10/23	MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Yiling Pharma's Hypertension Drug Passes Regulatory Evaluation in China	15/05/23	MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Yiling Pharma Wins Nod to Trial Prostate Cancer Drug	06/04/23	MT
Yiling Pharma Unit Gets Marketing Rights of Rujietai Capsules	02/03/23	MT
Shijiazhuang Yiling Pharma Appoints Founder as Honorary Chairman	28/02/23	MT
Yiling Pharma Gets Regulatory Nod for Traditional Chinese Medicine	03/02/23	MT
Yiling Pharma’s Antibiotic Passes Consistency Test	03/02/23	MT
Shijiazhuang Yiling’s Depression Drug Included in China’s Medical Insurance Catalog	20/01/23	MT
Yiling Pharma’s Traditional Chinese Medicine Added to Government's Recommended Drugs For COVID-19	09/01/23	MT
Gloom and boom: Fund managers' top picks for 2023	03/01/23	RE
Chinese Shares End Year With Modest Gains; Two Shenzhen Debutants Post Mixed Results	30/12/22	MT
Health Care Tick Down on Growth Fears -- Health Care Roundup	27/12/22	DJ
North American Morning Briefing : China Optimism Gives Boost to Futures	27/12/22	DJ
China stocks jump on easing COVID curbs	27/12/22	RE
China stocks rise on further eased COVID rules	27/12/22	RE

Chart Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Duration

Period

Chart Shijiazhuang Yiling Pharmaceutical Co., Ltd.

More charts

Company Profile

Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company principally engaged in research, development, production and sales of patented innovative traditional Chinese medicine. The Company operates three business sectors. The Proprietary Chinese Medicine sector is mainly engaged in multi-channel research and development of compound Chinese medicines, component Chinese medicines and single Chinese medicines. The Chemopharmaceutical sector mainly establishes chemopharmaceutical research and development platform, international standard production platform and network of overseas sales partners. The Health Industry sector has developed and launched a series of health products, including products of benefiting heart and brain, anti-aging and immunity, anti-fatigue and anti-joint, sleep and mood and Lianhua respiratory health. The Company also provides dietary supplements, healthy food and drink, disinfection products and personal protective equipment.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.9 CNY

Average target price

20.93 CNY

Spread / Average Target

+31.66%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-31.08%	3.6B
DONG-E-E-JIAO CO.,LTD.	+7.30%	4.81B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.71%	3.09B
TASLY PHARMACEUTICAL GROUP CO., LTD	-24.32%	2.62B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-11.35%	2.27B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+34.19%	1.82B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.49%	1.41B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-15.07%	1.38B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+40.95%	1.37B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-25.94%	1.29B

Alternative Medicine

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Equities

002603

CNE1000015S0

Pharmaceuticals

Tranche Update on Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 13, 2018.

Latest news about Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Chart Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Alternative Medicine